The Latest Prostate Cancer Breakthroughs Explained by a Leading Urologist
With Dr. Abraham Morgentaler and Dr. Marianne Brandon Listen to the podcast on all of your favorite platforms: Apple: https://podcasts.apple.com/ec/podcast... Spotify: https://open.spotify.com/show/0apSFzq... Find us on: Instagram: https://www.instagram.com/thesexdocto... Facebook: / thesexdoctors YouTube: / @thesexdoctorspod TikTok: / thesexdoctor LinkedIn (Dr. Abraham): / abraham-morgentaler-md-81628b6 LinkedIn (Dr. Marianne): / mariannebrandon-59224513 X (Dr. Abraham): https://x.com/DrMorgentaler X (Dr. Marianne): https://x.com/drbrandon In this episode, Dr. Brandon & Dr. Morgentaler discuss how testosterone therapy affects cholesterol, challenge long-held beliefs about prostate cancer treatment, and explore why some of medicine's biggest assumptions may deserve a second look. 00:00 – Podcast Kickoff: The episode opens with a listener question about how oral testosterone may affect cholesterol and heart health. 00:50 – Oral Testosterone Lipids: Dr. Morgentaler explains what testosterone therapy really does to cholesterol, ApoB, and overall cardiovascular risk. 06:29 – Conference ADT Debate: Fresh from a cancer conference, Dr. Morgentaler questions why androgen deprivation therapy remains the standard treatment. 22:41 – Why ADT Comes First: The doctors discuss why ADT is still used first despite newer therapies that may offer greater benefits. 24:54 – BAT and PSA Confusion: They break down bipolar androgen therapy (BAT) and explain why PSA levels don't always tell the full story. 32:28 – Huggins Myth and Wrap Up: Dr. Morgentaler revisits the decades-old research that shaped testosterone's reputation in prostate cancer and why it's worth questioning today. Resources: Huggins C, Hodges CV. Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer Research. 1941;1:293-297. Morgentaler A, Rhoden EL. Prevalence of Prostate Cancer Among Hypogonadal Men With Prostate-Specific Antigen Less Than 4.0 ng/mL and Normal Digital Rectal Examination: Results of a Biopsy Study. The Journal of Urology. 2006;175(2):495-499. Morgentaler A, Rhoden EL. Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring. New England Journal of Medicine. 2004;350:482-492. Tombal B, et al. The EMBARK Trial: Enzalutamide in Patients With High-Risk Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 2023. Denmeade SR, et al. Bipolar Androgen Therapy for Men With Castration-Resistant Prostate Cancer. (Johns Hopkins series of clinical trials and publications on BAT.) #testosteronetherapy #prostatecancertreatment #medicalinnovation
The Hidden Reason Some Married Men Have Affairs (From a Sex Therapist)
Testosterone 101: Why Normal Labs Don't Tell the Whole Story
Is Watchful Waiting The Right Thing To Do When You Have Prostate Cancer?
Stop Blind Biopsies: Near-Perfect Prostate Cancer Accuracy with Dr. Mark Emberton - EP 170
The Biggest Testosterone Therapy Lies Online Explained by Top Harvard Urologist
4 weeks post Prostatectomy
Why NOT radiation for prostate cancer?
Can Men Take Testosterone After Prostate Cancer? New Study Says This
The Devastating Effects Of Stage 4 Cancer
A Medical Oncologist Compares Surgery and Radiation for Prostate Cancer | Mark Scholz, MD | PCRI
The Real Reason Orgasms Change After 50
A future with No Prostate Biopsies with Mark Emberton, MD EP 86
"Ugh! It's Back!" What to Do When Prostate Cancer Returns
FDA's Newest Testosterone Update | What Men Need to Know
Many Men Chose The Wrong Prostate Cancer Treatment: Here’s Why
Dr. Robert Newton Reveals His Research on the Best Exercise Plan for Prostate Cancer Thrivers-141
Supraphysiologic Testosterone for Castrate Resistant Prostate Cancer with Dr. Michael Schweizer -185
Ep. 27 - The Best Supplements to Fighting Prostate Cancer
Restoring Sexual Function After Prostate Cancer Treatment - Tobias Kohler, MD Mayo Clinic
